BRCA2 and prostate cancer: However, the clinical relevance of germline and somatic defects in DDR genes remains largely unclear at present—the exception being germline BRCA2 mutations, which have been shown to be an independent prognostic factor for prostate cancer outcomes in different settings.13,15,25,26